硫辛酸补充与NELL1相关膜性肾病相关
硫辛酸是流行的非处方抗氧化补充剂,在多项临床试验中研究。一项多发性硬化临床试验中治疗组出现意外的高级别蛋白尿,促使在肾内科实践中发现相似患者。本文报告4例经活检证实的NELL1相关膜性肾病及1例疑似病例,均发生在硫辛酸补充后,停药和支持治疗后缓解。
要点
- 硫辛酸补充可能与NELL1相关膜性肾病有关。
- 临床表现可为高级别蛋白尿,需肾活检确诊。
- 停用硫辛酸并支持治疗后肾病缓解。
核心结论
- 硫辛酸补充与NELL1相关膜性肾病相关,停药和支持治疗后可缓解。
研究设计与样本
- 病例系列:4例经活检证实的NELL1相关膜性肾病及1例疑似病例,源于临床试验不良事件和肾内科实践发现。
主要发现
- 4例活检证实的NELL1相关膜性肾病和1例疑似病例发生在硫辛酸补充后。
- 停用硫辛酸并给予支持治疗后,患者获得缓解。
临床怎么用
- 对病因不明的膜性肾病患者,应询问硫辛酸补充史。
- 疑似硫辛酸相关NELL1膜性肾病时,停药并给予支持治疗可能诱导缓解。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Lipoic acid (alpha lipoic acid, thioctic acid) is a popular over-the-counter antioxidant and insulin-mimetic supplement under investigation in a variety of conditions including multiple sclerosis, diabetes, and schizophrenia. Unfortunately, high-grade proteinuria was an unexpected adverse event specific to the treatment arm of our clinical trial investigating lipoic acid supplementation in patients with multiple sclerosis. This observation led to detection of similar patients in our nephrology practice. Here, we describe four biopsy-proven cases of neural epidermal growth factor-like 1 (NELL1)-associated membranous nephropathy following lipoic acid supplementation and a fifth suspected case. Discontinuation of lipoic acid and supportive therapy resulted in remission.
引用
- Spain RI, Andeen NK, Gibson PC, et al. Lipoic acid supplementation associated with neural epidermal growth factor-like 1 (NELL1)-associated membranous nephropathy. Kidney Int. 2021. PMID: 34662650. doi:10.1016/j.kint.2021.10.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。